Longevity Intelligence

PHASE 1Life Biosciences ER-100 — first-ever partial epigenetic reprogramming in humans, FDA-cleared Jan 2026 PHASE 1Retro Biosciences RTR242 — first-in-human dose Adelaide Dec 2025, AI-designed Yamanaka variants CAPITALAltos Labs $3B preclinical, Sentinel Cell program 2026 PHASE 2Intervene Immune TRIIM-X enrolling — 2.5yr biological age reversal in original 9-man trial SIGNALBuck Institute 2025: TPE+IVIG cut biological age 2.61 years on multi-omic clocks REGFDA Category 2 on BPC-157 — most peptide compounding restricted 2024-2025 RXSELECT trial: semaglutide cut cardiovascular events 20% in non-diabetics FRONTIERStem Cell Institute Panama — 'Golden Cells' umbilical cord MSCs, no FDA jurisdiction PHASE 1Life Biosciences ER-100 — first-ever partial epigenetic reprogramming in humans, FDA-cleared Jan 2026 PHASE 1Retro Biosciences RTR242 — first-in-human dose Adelaide Dec 2025, AI-designed Yamanaka variants CAPITALAltos Labs $3B preclinical, Sentinel Cell program 2026 PHASE 2Intervene Immune TRIIM-X enrolling — 2.5yr biological age reversal in original 9-man trial SIGNALBuck Institute 2025: TPE+IVIG cut biological age 2.61 years on multi-omic clocks REGFDA Category 2 on BPC-157 — most peptide compounding restricted 2024-2025 RXSELECT trial: semaglutide cut cardiovascular events 20% in non-diabetics FRONTIERStem Cell Institute Panama — 'Golden Cells' umbilical cord MSCs, no FDA jurisdiction